Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Obesity Medicine
•
Primary Care
How do you decide whether to reinitiate a GLP-1 agonist after a patient has experienced acute pancreatitis while on this therapy?
Answer from: at Community Practice
Will not try it again, given the seriousness of the side effect, and in most cases, there are alternatives.
Sign in or Register to read more
27578
Related Questions
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
What strategies do you recommend to address the negative self-talk/internalized bias that patients carry about their own weight?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
Do you recommend the use of GLP1 R agonist therapy in patients with T1DM for weight loss?
How do you counsel patients on GLP-1 agonists for weight loss who wish to space out their medication or take a "drug holiday" to temporarily increase their appetite?
How should we approach the recommendation of intermittent fasting for weight loss in patients with pre-existing cardiovascular conditions, given the observed association of increased CV mortality with eating durations of less than 8 hrs?
How do you approach the use of GLP-1 receptor agonists for the management of patients with metabolically healthy obesity?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
What strategies do you employ for adjusting the dosage of levothyroxine in hypothyroid patients who experience significant weight loss or are initiated on GLP-1 receptor agonists?
Do you routinely check vitamin K levels in post-bariatric surgery patients?